Thrombolytic studies of Streptokinase from Streptococcus pyogenes

Life would not long remain possible in the absence of microbes. Many of common problems in clinical practice today relate to thrombosis. Streptokinase is the first thrombolytic drug to be described and was introduced for myocardial infarction more than 40 years ago. It is now the leading thrombolytic agent and is included in the World Health Organization (WHO) model list of essential medicine. A failure of hemostasis and consequent development of blood clots in the circulatory system can produce severe consequences such as acute myocardial infarction and ischemic stroke, both leads to cause of death. Pathological development of blood clots requires clinical intervention with fibrinolytic agents such as tissue plasminogen activator and streptokinase. This book deals with streptokinase as a clinically important and plasminogen activator by the studies.

Autorentext

O Dr. Vaibhav Dagaji Aher concluiu o bacharelato em Farmácia, o mestrado em Biotecnologia Farmacêutica, o doutoramento em Ciências Farmacêuticas e tem experiência de investigação pós-doutoral na Índia e nos EUA no domínio da imunologia, toxicologia e saúde radiológica.